Results 71 to 80 of about 795 (185)
Background Osteoporosis is a metabolic bone disease. Bisphosphonate (BP) and eldecalcitol (ELD) are two clinical first-line drugs for osteoporosis patients. However, the effect of ELD + BP vs. BP alone on osteoporosis treatment is still unclear.
Zaoqian Zheng, Jinyu Luo
doaj +1 more source
High frequency:Low frequency ratios over time.
(A) capecitabine, (B) eldecalcitol, (C) epoetin beta pegol, (D) peginterferon alfa-2a, and (E) sevelamer hydrochloride.
Seigo Okugawa (733308) +10 more
core +1 more source
Background Subtrochanteric fracture is a recognized complication following osteosynthesis for femoral neck fractures, typically occurring within 1–2 months postoperatively. At the time of onset, incomplete healing of the femoral neck fracture often results in a complex fracture configuration that poses challenges for management.
Hirokazu Takai +8 more
wiley +1 more source
Alfacalcidol (ALF) and eldecalcitol (ELD) are vitamin D analogues that can be combined with anti-resorption drugs, such as bisphosphonate (BP) for the treatment of osteoporosis (OP). There has been no report comparing the effects of those vitamin D analogs in combination with BPs.
Mukaiyama, Keijiro +6 more
openaire +3 more sources
Background The incidence of diabetic osteoporosis is increasing. This article evaluates the effect of combination treatment with the hypoglycemic drug exendin-4 (Ex-4) and the vitamin D analog eldecalcitol (ED-71) on improving diabetic osteoporosis and ...
Yupu Lu +6 more
doaj +1 more source
Adverse drug reaction reporting trend for 5 drugs.
Total number of individual case safety reports for (A) capecitabine, (B) eldecalcitol, (C) epoetin beta pegol, (D) peginterferon alfa-2a, and (E) sevelamer hydrochloride.
Seigo Okugawa (733308) +10 more
core +1 more source
Abstract Twelve years after the first edition of The Guideline for Gynecological Practice, which was jointly edited by The Japan Society of Obstetrics and Gynecology and The Japan Association of Obstetricians and Gynecologists, the 5th Revised Edition was published in 2023.
Eiji Nishio +35 more
wiley +1 more source
The proportion of adverse drug reactions reported to the manufacturer within 2 weeks of onset.
(A) capecitabine, (B) eldecalcitol, (C) epoetin beta pegol, (D) peginterferon alfa-2a, and (E) sevelamer hydrochloride. Error bars represent the 95% confidence intervals.
Seigo Okugawa (733308) +10 more
core +1 more source
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses, and clinically characterised by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous‐violaceous edges. Underlying diseases include rheumatoid arthritis, inflammatory bowel disease, haematopoietic malignancy ...
Hitomi Sugino +4 more
wiley +1 more source
Pd(0)‐Catalyzed‐Mediated Synthesis of Vitamin D Compounds
Abstract 1α,25‐Dihydroxyvitamin D3 (1,25D3), the hormonally active form of vitamin D3, regulates mineral homeostasis, cell growth, cell differentiation‐proliferation, apoptosis, and immune responses. 1,25D3 activates more than 229 genes associated with several diseases, including arthritis, diabetes and cancer, suggesting its implications in a broader ...
Antonio Mouriño
wiley +1 more source

